Skip to content
ES
MARKETS / NASDAQ / BGM
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

BGM Group Ltd. BGM

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$37.9M
▲ 51.1% YoY
$-19.9M
$-3.9M
▼ 1395.3% YoY
In brief

What this company does

BGM Group Ltd (“BGM”) is not an operating company but a Cayman Islands holding company. BGM’s operations are conducted through contractual arrangements with the VIE based in China. BGM Group Ltd. has a strategic focus on the technology fields of AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals. The WFOE and the VIE and its subsidiaries operate a pharmaceutical and chemical company based in China that focuses on the development, manufacture, marketing, and sale of oxytetracycline products, licorice products, traditional Chinese medicine derivatives (“TCMD”) product, heparin product, sausage casings, and fertilizers. The products of the VIE and its subsidiaries are sold in more than 20 provinces in China. The WFOE and the VIE and its subsidiaries currently manufacture ten products.

Written from the business description in BGM Group Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 21 July 2026. Every sentence was checked against that document before publication.

Growth
USD 37.9M
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2025 · Revenue 37.9 · Net income -19.9
25.0M50.0M-8.0M-16.0M20182019202020212022202320242025
Compound annual growth
−16.4%
−5.4%
+19.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −5.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−53 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -33.2% · Net -53.3%
5%10%-20%-40%20182019202020212022202320242025
ROE
FY2025 · ROE -9.2%
10%20%-5%-10%-15%20182019202020212022202320242025
Gross margin16.6%
Operating margin-33.2%
Net margin-53.3%
Return on assets-8.3%
EBITDAUSD -11.1M

Each USD of equity lost 9 cents this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -3.9
4M8M-2M20182019202020212022202320242025
Net buybacks $M Dividends $M
FY2023 · Dividends 1.8 · Net buybacks —
0.8M1.6M20182023
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 433.8M
EquityUSD 390.9M
CashUSD 9.8M
Current ratio1.24×

Equity funds 90% of total assets.

The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018
Revenue $B0.00.00.00.10.10.10.00.1
Operating income $B−0.0−0.0−0.00.00.00.00.00.0
EBITDA $B−0.00.0−0.00.00.00.00.00.0
Income tax $B0.0−0.00.00.00.00.00.00.0
Net income $B−0.0−0.0−0.00.00.00.00.00.0
Free cash flow $B−0.00.00.00.0−0.00.0−0.00.0
EPS, diluted $−0.18−0.20−1.080.150.090.170.180.17
Dividend / sh $········
Payout %··−23····14
ROE %−9.2−3.4−16.22.07.822.029.7·
Shares out B0.200.010.010.010.040.030.03·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 38 reconciliationsAUDITED

Reconciled in 8 of 19 fiscal years. 57 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsSeptember 30
SEC categoryemerging growth company
Data on record since2018

Share this section

Download image